CRL4 Inhibitors Targeting E2-Ub Conjugate Interface
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective small molecule inhibitors targeting the catalytic activity of Cullin-RING E3 ubiquitin ligases (CRLs), which are crucial for protein degradation and implicated in various physiological and pathological processes, including cancer, due to the 'undruggable' nature of RING-type E3 enzymes.
Innovation Solution
Development of novel high-throughput screening (HTS) platforms and medicinal chemistry optimization led to the identification of compounds #33-11 and KH-4-43, which inhibit CRL4's catalytic activity by binding to its core complex, disrupting ubiquitination and causing substrate stabilization, thereby inhibiting CRL4-mediated processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional structure-based ligand search methods are used to target RING-type E3 enzymes, then the method is simple and familiar, but the large flat interfaces of RING domains make them 'undruggable' and screening fails to identify effective inhibitors
Solution Approach 1:
The patent introduces an E2-Ub conjugate as an intermediary component to mediate the interaction between the small molecule inhibitor and the RING domain. Instead of directly targeting the difficult-to-drug RING domain interface, the compound binds to the E2-Ub conjugate, which then disrupts the E2-E3 interaction. This intermediary approach converts an 'undruggable' target into a druggable system by creating a ternary complex binding scenario.
Solution Approach 2:
The patent segments the ubiquitination system into distinct components (E2, Ub, RING domain, substrate) and targets the interaction interface between E2-Ub and RING domain separately. By focusing on the E2-E3 interface rather than the entire ubiquitination pathway or the RING domain alone, the screening method isolates a specific druggable interface that can be targeted by small molecules.
2Productivity
If high-throughput screening is performed to identify CRL inhibitors, then compound discovery potential increases, but screening complexity and resource requirements increase significantly
Solution Approach 1:
The patent performs preliminary assembly of the E2-Ub-CRL ternary complex before screening, pre-validating the functional interaction. This preliminary action ensures that only compounds that disrupt a pre-formed, validated complex are identified, reducing false positives and simplifying hit validation. The pre-assembled complex serves as a ready-to-screen platform that reduces the complexity of during-screening validations.
Solution Approach 2:
The patent creates a simplified in vitro copy of the ubiquitination system using purified recombinant proteins (E2, Ub, CRL) rather than requiring complex cellular extracts. This copied system maintains the essential functional interactions while eliminating cellular complexity, enabling high-throughput screening with reduced resource requirements and simplified data interpretation.
3Manufacturing precision
If small molecules are designed to bind RING domain interfaces, then direct E3 inhibition is achieved, but the large flat interface area makes specific high-affinity binding difficult
Solution Approach 1:
Instead of attempting to bind the entire large RING domain interface, the patent focuses on a specific local region: the E2-Ub conjugate binding site. By targeting this localized region with the small molecule, the method achieves specific high-affinity binding without requiring interaction with the entire large interface. The inhibitor binds locally to the E2-Ub conjugate, creating a focused interaction that overcomes the size disadvantage.
Data Source
AI summary
Disclosed herein are compounds that inhibit cullin-RING E3 ubiquitin ligase 4, a method of inhibiting the catalytic activity of a Cullin-RING E3 Ubiquitin (Ub) Ligase (CRL) in a cell, compositions comprising the inhibitor compounds, a method of treating a tumor, and a method of treating a subject for cancer.